BioTime, CIRM reach deal on embryonic stem cell lines

BioTime, an Alameda, CA-based company specializing in regenerative medicine, will provide five clinical-grade human embryonic stem cell lines to the California Institute for Regenerative Medicine, according to an announcement Monday.

CIRM is the agency created when California voters supported a $3 billion funding measure for stem cell-related research. Under the agreement, BioTime will initially provide research grade cell lines, and within one year, BioTime will also make available GMP-grade cell lines along with certain documentation and complete DNA sequence information.

They expect that the use of the GMP-grade cell lines may streamline the translation of basic science to human therapies. If users of the cell lines and BioTime eventually sign definitive license agreements for commercial use of the cell lines, BioTime will receive a royalty on net sales.

- read the BioTime release
- and here's the Genetic Engineering & Biotechnology News brief

Suggested Articles

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.